PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer
about
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancerPrognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature ReviewMolecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary fieldPushing the envelope in the mTOR pathway: the second generation of inhibitorsPhenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survivalColorectal cancer tumour markers and biomarkers: Recent therapeutic advancesMolecular phenotypes of colorectal cancer and potential clinical applicationsMolecular alterations and biomarkers in colorectal cancerCombined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumorsKRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerOncogenic mutations of PIK3CA in human cancersExpression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer CellsPrognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysisThe determinants of head and neck cancer: Unmasking the PI3K pathway mutationsDifferential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study.Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics.Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer.PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset.The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patientsEGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancerEpigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors.A simple and cost-effective method of DNA extraction from small formalin-fixed paraffin-embedded tissue for molecular oncologic testingPIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.Recurrent inflammatory myofibroblastic tumors harboring PIK3CA and KIT mutations.PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method.NRAS mutations are rare in colorectal cancer.A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.Colorectal cancer molecular biology moves into clinical practice.Clinical implications of the cancer genomeBRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review
P2860
Q21142734-72C7FB03-73D4-4D5D-B023-C0550F9929D6Q24289005-E3A3BC6E-3977-4944-B02E-5528DAA7BFD6Q24620628-AA0F4107-79D3-4B23-92CD-F5465221EF85Q24622222-06445356-542C-48AF-AC91-F68C02D342B4Q24626799-6C0F044C-A4E6-4716-9ABB-AD45C6612489Q26768427-DFDF4396-2F99-417D-80B4-B3F47127D19FQ26785725-2DF31ADD-F02C-4050-85EF-DE28B396723DQ26862317-7CD7939B-6ABE-444D-B34D-62F6BAA688D9Q27349020-EC0822BC-944E-49F5-ABDA-D36833373B1CQ27851532-03FAC56E-51E3-4648-8824-AC60C653AD64Q28076490-0DF945D1-FD54-460B-9535-A749F9FFDCA7Q28284802-9E36EAE5-0204-4D1C-88E3-B2189ABAD1A9Q28534094-9B5387FF-94B2-4C25-9C9B-34F3EC472747Q30248900-BF675268-9545-457C-B1F4-44C3DBA9F2B2Q30365726-EA4EB4A9-7D71-4558-9348-1C92731AE733Q30492318-5D38CE3B-36A7-4ECF-990D-61D8E655307FQ31157634-3899A8F1-7FD8-4E31-9046-AC57323A96A6Q33514878-6F23C197-8EAB-4077-A95A-B65F7BF26616Q33526301-C25D5201-BB1E-4B7F-A699-5C6C74EB34D0Q33541323-AFAC10E6-0747-40FA-9821-B1588D777B1BQ33637161-CE4B39F4-9681-4099-AFBA-46578A2294ABQ33723499-6B2B5E5F-9C80-43C4-A1BC-6F726D30938CQ33745140-55A698EB-B351-4221-AB79-50C7C0655D86Q33754380-B935EF38-91C0-4E06-84E7-B7CF863598E8Q33770769-977995B6-A40B-4ECB-9F84-C75933F990B2Q33783108-DE712342-5644-45C4-B1B9-6157D27DF1F1Q33809458-06C4795B-0516-4E30-97BE-BDF9EEEAF47CQ33856378-23DDE72C-4024-4E8C-BD68-17986F0FD34CQ33942280-2B66BB54-D98F-4778-9A1B-85863C6A6B56Q33947516-5A545BC5-4756-4565-9234-3ED642E17AF1Q33987852-039CFDB3-F18C-4D40-B768-8D7AC17C1329Q34028920-C52ACD29-1C6B-449F-8DB6-3E2DDBEAC8B9Q34084868-6E5A6D95-7AF0-4692-A10A-8F4BE4C995C3Q34091172-3D6FA85F-A7C1-4AC2-8B23-731D606ADCBCQ34138308-E33D194F-ADC6-415B-A0DA-44A85ACF4472Q34153696-4925BE50-2763-4046-835A-958E943B9760Q34425013-A26984D4-EF1B-45BB-9EC5-572CE5660FBCQ34488700-BB63C58C-B7E1-4803-8668-6941C2B0780DQ34517338-C26D2BDC-AB26-4793-9EB2-C5055355A532Q34551974-188177EB-5969-4E2A-B611-893BB389001A
P2860
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PIK3CA mutation is associated ...... ratively resected colon cancer
@en
PIK3CA mutation is associated ...... atively resected colon cancer.
@nl
type
label
PIK3CA mutation is associated ...... ratively resected colon cancer
@en
PIK3CA mutation is associated ...... atively resected colon cancer.
@nl
prefLabel
PIK3CA mutation is associated ...... ratively resected colon cancer
@en
PIK3CA mutation is associated ...... atively resected colon cancer.
@nl
P2093
P2860
P50
P356
P1476
PIK3CA mutation is associated ...... ratively resected colon cancer
@en
P2093
Andrew T Chan
Gregory J Kirkner
Jeffrey A Engelman
Kaori Shima
Katsuhiko Nosho
Natsumi Irahara
Shoko Kure
P2860
P304
P356
10.1200/JCO.2008.18.6544
P407
P577
2009-02-23T00:00:00Z